Archive

The PHOENIX group underlined its position as a leading healthcare provider in Europe in the first three quarters of the fiscal year 2015/16. The company’s overall performance in the European market continued developing very positively. Total operating performance, including revenue as well as…

The PHOENIX group underlined its position as a leading healthcare provider in Europe in the first half of the fiscal year 2015/16. The company’s overall performance in the European market continued developing very positively. Total operating performance, which includes revenue as well as handled…

The appropriate competition authorities have unconditionally approved the acquisition of the Slovakian company SUNPHARMA by the PHOENIX group. The PHOENIX group had announced the acquisition of SUNPHARMA back in January 2015 – subject to approval by the antitrust authorities. The company operates 42…

The PHOENIX group consolidated its position as a leading healthcare provider in Europe in the first quarter of the fiscal year 2015/16. The company’s overall performance in Europe exceeded that of the market as a whole. Total operating performance, including revenue as well as handled volume for…

The PHOENIX group brought the fiscal year 2014/15 to a successful close, expanding its position as a leading healthcare provider in Europe despite the challenging European market environment. Total operating performance, including revenue as well as handled volume (handling for service charge), rose…

The PHOENIX group intends to acquire the Hungarian company Novodata. The acquisition is subject to approval by the relevant competition authorities. Since its founding in 1988, Novodata has been successfully operating in the Hungarian healthcare market with its pharmacy software and is now the…

The PHOENIX group is celebrating the company’s 20th anniversary today. In 1994, Adolf Merckle founded PHOENIX Pharmahandel Aktiengesellschaft & Co from the German regional wholesalers F. Reichelt AG in Hamburg, Otto Stumpf GmbH in Berlin, Ferdinand Schulze GmbH & Co. in Mannheim, Otto Stumpf AG in…

PHOENIX plans to acquire the Slovakian company SUNPHARMA, which operates 42 pharmacies in Slovakia and eight in the Czech Republic. The pharmacies are located in prime areas such as shopping centres. The acquisition is subject to approval by the relevant competition authorities. The parties have…

The PHOENIX group underlined its position as Europe’s leading pharmaceutical trader in the first three quarters of 2014/15. “We are pleased with the development – the improved results of operations in Western and Northern Europe in particular confirm that we are heading in the right direction.

The planned purchase will make Brocacef a leading service provider in the Dutch healthcare market. With a total of 5,300 employees and revenue of EUR 2.1 billion, Brocacef continues to expand its range, and by acquiring the pre-wholesale activities, it will be able to offer more comprehensive…

The PHOENIX group consolidates its position in Europe as leading pharmaceutical trader in the first half of 2014/15. “We are pleased with the development in the first half of 2014/15, and our success is confirmed in particular by the improved results of operations in Western and Northern Europe”,…

The PHOENIX group is taking advantage of the current attractive market environment and has successfully issued another corporate bond. This bond marks the third successful emission by the pharmaceutical trader. After the issuance of the inaugural bond in July 2010, the PHOENIX group strengthened its…

The PHOENIX group underlined its position as Europe’s leading pharmaceutical trader in the first quarter of the fiscal year 2014/15. Revenue increased by 2.1 per cent compared with the same period of the previous year to EUR 5,452.0 million in the first quarter of 2014/15.

The PHOENIX group continued to secure its position as Europe’s leading pharmaceutical trader in the fiscal year 2013/14, despite the challenging European market environment. Revenue rose by 2.7 per cent to EUR 21,792.4 million. This was due to the higher revenues in Finland, Italy, the Netherlands,…

The PHOENIX group once again underlined its position in Europe as leading pharmaceutical trader in the first three quarters of the 2013/14 fiscal year. Revenue increased by 2.8 per cent (3.6 per cent after adjustment for exchange rate effects) compared with the same period of the previous year to…

Today the PHOENIX group has announced several planned organizational changes in the structure of PHOENIX in Germany. These measures are part of the group-wide optimization programme PHOENIX FORWARD initiated in January 2013 which aims to achieve annual cost savings of EUR 100 million Europe-wide.

Reimund Pohl, Chief Executive Officer of PHOENIX Pharmahandel GmbH & Co KG (PHOENIX group), will retire as scheduled by the end of the fiscal year 2013/14 on 31 January 2014 after having worked for the company for 32 years. Effective from 1 February 2014, Oliver Windholz, Executive Board Member for…

The PHOENIX group underlines its position as Europe’s leading pharmaceutical trader in the first half of 2013/14. “In the first half of 2013/14 we performed well in a persistently challenging market environment, with business developing particularly well in Northern and Eastern Europe”, said Reimund…

Dr. Michael Majerus, CFO of PHOENIX Pharmahandel GmbH & Co KG (PHOENIX group), responsible for finance, controlling, accounting and taxes will leave the company effective from 31. August 2013 by mutual consent after having successfully implemented a new financing structure in the PHOENIX group. Dr.…

The PHOENIX group underlines its position as a leading pharmaceutical trader in Europe on the basis of its dynamic business development in the first quarter of the 2013/14 fiscal year. In the first quarter of 2013/14, revenue increased by 2.7 per cent compared with the same period of the previous…

PHOENIX group is taking advantage of the current attractive market environment and has – following its inaugural bond in July 2010 – successfully issued another corporate bond. More than 100 investors were met during a very well-received pan-European road show in Frankfurt am Main, London, Paris,…

The PHOENIX group ends the 2012/13 fiscal year on a positive note despite a challenging European market environment. The company has further extended its position as a leading pharmaceutical trader in Europe. Revenue only experienced a moderate decline of 2 per cent to EUR 21,218.7 million compared…

With its sustainable growth strategy the PHOENIX group has positioned itself as leading pharmaceutical distributor in Europe. “The PHOENIX group can proudly look back on the highly successful development of its business operations.